Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14525304 | 0.84 | HSD17B1 (0.50) | ERN1MAPTKMT2A | |
| SCHEMBL14524960 | 0.81 | EGFR (0.52) | ERN1EGFRALDH1A1MAPTMEN1 | |
| SCHEMBL2806958 | 0.81 | ERN1 (0.73) | ERN1EGFRALDH1A1CA12CA1 | |
| SCHEMBL14524968 | 0.81 | ERN1 (0.65) | ERN1CA12CA1CA2CA9 | |
| SCHEMBL12767865 | 0.81 | ERN1 (1.00) | ERN1EGFRALDH1A1CA12CA1 | |
| SCHEMBL4599080 | 0.79 | ERN1 (0.72) | ERN1ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL2809056 | 0.78 | EGFR (0.52) | ERN1EGFRALDH1A1MAPTMEN1 | |
| SCHEMBL14524874 | 0.77 | HTT (0.54) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL8175589 | 0.77 | KDM4E (0.48) | ERN1EGFRALDH1A1MAPTKDM4E | |
| SCHEMBL14609776 | 0.76 | ERN1 (0.39) | ERN1ALDH1A1MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | ERN1 4124/4885EGFR 705/4885ALDH1A1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.